Nkar­ta signs its name to an am­bi­tious fu­ture with man­u­fac­tur­ing hub for not one but mul­ti­ple mar­ket­ed drugs

Rid­ing sci­ence out of Dario Cam­pana’s famed lab in Sin­ga­pore, West Coast biotech Nkar­ta has been a high-pro­file en­try in­to the race for the in­dus­try’s first nat­ur­al killer cell-based ther­a­py. The biotech, miles away from a po­ten­tial ap­proval, is dou­bling down on its own am­bi­tion and set­ting up a man­u­fac­tur­ing fa­cil­i­ty of the fu­ture far in ad­vance.

Nkar­ta has signed a lease on an 88,000-square-foot fa­cil­i­ty in South San Fran­cis­co that will act as the biotech’s new head­quar­ters as well as the home of its com­mer­cial man­u­fac­tur­ing op­er­a­tions, the com­pa­ny said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER